Data from Irving, Texas-based Reata Pharmaceuticals Inc.'s phase II Cardinal study with bardoxolone in patients with chronic kidney disease (CKD) due to Alport syndrome whetted investor appetite for the phase III portion of the study, which includes a placebo arm and looks likely to win.